Abbreviations
- ASBT
apical sodium‐dependent bile acid transporter
- BA
bile acid
- BSEP
bile salt export pump
- CA
cancer antigen
- CDCA
chenodeoxycholic acid
- Chol
cholesterol
- Col1α, collagen 1α; COX2
cyclooxygenase 2
- eNOS
endothelial NO synthase
- ET1
endothelin 1
- FA
fatty acid
- FFA
free fatty acid
- FGF
fibroblast growth factor
- FGFR
FGF receptor
- FXR
farnesoid X receptor
- HCC
hepatocellular carcinoma
- HDL
high‐density lipoprotein
- IFN
interferon
- IGF1R
insulin‐like growth factor 1 receptor
- IL
interleukin
- iNOS
inducible NO synthase
- KC
Kupffer cell
- LDL
low‐density lipoprotein
- LDLr
LDL receptor
- Lp(a), lipoprotein a; LSEC
liver sinusoidal endothelial cell
- MCP1
monocyte chemoattractant protein 1
- MDR
multidrug resistance
- MMP
matrix metalloproteinase
- NAFLD
nonalcoholic fatty liver disease
- NASH
nonalcoholic steatohepatitis
- NFκB
nuclear factor kappa B
- NO
nitric oxide
- NTCP
sodium/taurocholate cotransporting polypeptide
- PL
phospholipids
- SR‐BI
scavenger receptor class B type 1
- p‐STAT3
phosphorylated signal transducer and activator of transcription 3
- TG
triglyceride
- TGF
transforming growth factor
- TIMP
tissue inhibitor of metalloproteinase
- TJ
tight junction
- TNF
tumor necrosis factor
- VCAM
vascular cell adhesion molecule
- VLDL
very low‐density lipoprotein
- ZO‐1
zona occludens 1.
Potential conflict of interest: Dr. Trauner consults, is on the speakers’ bureau, and received grants from Falk and Gilead. He consults and is on the speakers’ bureau for MSD. He consults and received grants from Intercept and Albireo. He is on the speakers’ bureau and received grants from Roche. He consults for Phenex and Novartis. Dr. Reiberger consults for Xtuit and received grants from Phenex. He received grants and speaker honoraria from Roche, Gilead, and MSD.
References
- 1. Neuschwander‐Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al., Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial. Lancet 2015;385:956–965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, et al. Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2Ð/Ð (Abcb4Ð/Ð) mouse cholangiopathy model by promoting biliary HCOÐ3 output. Hepatology 2011;54:1303–1312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006;7;103:3920–3925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo‐controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631–643. [DOI] [PubMed] [Google Scholar]
- 5. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014;59:2286–2298. [DOI] [PubMed] [Google Scholar]